Aktieselskabet Schouw & Co.
Schouw & Co. share buy-back programme, week 4 2026
Schouw & Co. share buy-back programme, week 4 2026
On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026.
The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).
| Trading day | No. of shares | Average price | Amount DKK | ||
| Accumulated until 16 January 2026 | 30,000 | 673.03 | 20,190,970 | ||
| Monday, 19 January 2026 | 3,330 | 673.90 | 2,244,087 | ||
| Tuesday, 20 January 2026 | 3,700 | 664.95 | 2,460,315 | ||
| Wednesday, 21 January 2026 | 2,970 | 661.68 | 1,965,190 | ||
| Thursday, 22 January 2026 | 3,000 | 673.50 | 2,020,500 | ||
| Friday, 23 January 2026 | 3,000 | 672.00 | 2,016,000 | ||
| In the period 19 January 2026 - 23 January 2026 | 16,000 | 669.13 | 10,706,092 | ||
| Accumulated until 23 January 2026 | 46,000 | 671.68 | 30,897,062 | ||
| Following the above transactions, Schouw & Co. holds a total of 2,288,793 treasury shares corresponding to 9.16% of the total share capital of 25,000,000 shares. | |||||
Aktieselskabet Schouw & Co.
Jørgen Dencker Wisborg, Chairman
Jens Bjerg Sørensen, President, telephone number +45 86 11 22 22
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Coloplast A/S26.1.2026 13:02:08 CET | Press release
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET
Minerva Neurosciences, Inc26.1.2026 13:00:00 CET | Press release
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Calian Group Ltd.26.1.2026 13:00:00 CET | Press release
Calian Mobilizes Initial $100 Million to Accelerate Canada’s C5ISRT Defence Capabilities
Tryg A/S26.1.2026 12:10:37 CET | Press release
Tryg - Transactions in connection with share buyback programme
Suominen Corporation26.1.2026 12:00:00 CET | Press release
Proposals by the Nomination Board to the Annual General Meeting 2026 of Suominen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom